Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The firm is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. The company is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Follow-Up Questions
What is the price performance of RKVTF stock?
The current price of RKVTF is $0.2894, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Rakovina Therapeutics Inc?
Rakovina Therapeutics Inc belongs to N/A industry and the sector is N/A
What is Rakovina Therapeutics Inc market cap?
Rakovina Therapeutics Inc's current market cap is $6.1M
